Discounted Cash Flow (DCF) Analysis Levered
Cellectar Biosciences, Inc. (CLRB)
$2.91
+0.13 (+4.68%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 2.91 |
|---|---|
| Beta | 1.335 |
| Diluted Shares Outstanding | 7.06 |
| Cost of Debt | |
| Tax Rate | 0.21 |
| After-tax Cost of Debt | -49.74% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 11.036 |
| Total Debt | 0.60 |
| Total Equity | 20.53 |
| Total Capital | 21.14 |
| Debt Weighting | 2.86 |
| Equity Weighting | 97.14 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | - | - | - | - | - |
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 9.30 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -19.26 |
| Equity Value | - |
| Shares Outstanding | 7.06 |
| Equity Value Per Share | - |